PUBLIC POLICY MANAGEMENT GROUP for HCA HOSPITAL CORPORATION OF AMERICA
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Insurance INS
Monitored implementation of the Affordable Care Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| PARKER SHERRILL | — |
| WARREN TARDY | — |
Taxation/Internal Revenue Code TAX
Monitored implementation of PL 115-97 Tax Cuts and Jobs Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| PARKER SHERRILL | — |
| WARREN TARDY | — |
Health Issues HCR
HR 1156 Patient Access to Higher Quality Health Care Act of 2017 (all sections of full text) S 1133 Patient Access to Higher Quality Health Care Act of 2017 (all sections of full text) HR 277 American Health Care Reform Act of 2017 (all sections of full text) Discussions seeking guidance to minimize supply chain shortages for areas hit by natural disasters Monitored S 297 Increasing Competition in Pharmaceuticals Act Monitored HR 749 Lower Drug Costs trough Competition Act Monitored HR 208 Ensuring Health Care Opportunities Act Monitored S 1115 Making Pharmaceutical Markets More Competitive Act Monitored HR 2562 Making Pharmaceutical Markets More Competitive Act Monitored S191 Patient Freedom Act of 2017 Monitored S761 Health Care Options Act of 2017 Monitored HR1933 Health Care Options Act of 2017 Monitored HR 1628 American Health Care Act of 2017 Monitored Bipartisan Health Care Stabilization Act of 2017 (proposed Alexander-Murray legislation) Monitored The Lower Premiums Through Reinsurance Act of 2017 (proposed Collins-Nelson legislation) Monitored S 2312 Helping Ensure Low-income patients have Access to Care and Treatment (HELP) Act Monitored politically appointed Senate-confirmed positions Monitored PL 115-141 Consolidated Appropriations Act, 2018 Monitored HR 4191 HHS Cybersecurity Modernization Act Monitored HR 4710 340B PAUSE Act Monitored HR 4392 To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PARKER SHERRILL | — |
| WARREN TARDY | — |
Medicare/Medicaid MMM
Discussions pertaining to budget sequestration limits on Medicare spending Discussions involving nominations to federally authorized commissions Discussions pertinent to proposed reduction in the amount of Medicare bad debt payments to hospitals for Medicare beneficiaries who fail to pay their cost-sharing obligations for treatments provided by the hospital Monitored HR 1130 Fair Medicare Hospital Payments Act of 2017 Monitored S41 Medicare Prescription Drug Price Negotiation Act of 2017 Monitored HR 242 Medicare Prescription Drug Price Negotiation Act of 2017
| Lobbyist | Covered position, as disclosed |
|---|---|
| PARKER SHERRILL | — |
| WARREN TARDY | — |
Budget/Appropriations BUD
Discussions related to federal natural disaster assistance for hospitals and The Stafford Act Monitored discussions pertaining to the Presidents FY2019 HHS Budget
| Lobbyist | Covered position, as disclosed |
|---|---|
| PARKER SHERRILL | — |
| WARREN TARDY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.